Anticorps Polyclonal de lapin anti-ABHD18

ABHD18 Polyclonal Antibody for WB, IHC, IF/ICC, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, IF/ICC, Indirect ELISA

Conjugaison

Non conjugué

N° de cat : 25036-1-PBS

Synonymes

C4orf29, Abhydrolase domain-containing protein 18, Alpha/beta hydrolase domain-containing protein 18, Protein ABHD18



Informations sur le produit

25036-1-PBS cible ABHD18 dans les applications de WB, IHC, IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène ABHD18 Protéine recombinante Ag19120
Nom complet chromosome 4 open reading frame 29
Masse moléculaire calculée 414 aa, 47 kDa
Poids moléculaire observé 60 kDa
Numéro d’acquisition GenBankBC128143
Symbole du gène C4orf29
Identification du gène (NCBI) 80167
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

ABHD18 (α/β hydrolase domain-containing protein 18) is a transmembrane protein in mammals whose function has not yet been fully elucidated. It belongs to the large α/β hydrolase superfamily, whose members typically possess hydrolase activity and are involved in a variety of metabolic reactions. The ABHD18 protein is localized on the lysosomal membrane and may participate in intracellular lipid metabolism or signal transduction processes. Recent studies have shown that ABHD18 is the key enzyme in human cells that catalyzes the deacylation of cardiolipin to MLCL. The loss of ABHD18 function can significantly alleviate mitochondrial supercomplex defects, energy metabolism disorders, and cardiomyopathy phenotypes caused by TAZ deficiency, even achieving a "genetic suppression" effect in mice and patient cells. This not only reveals ABHD18 as a core node in the cardiolipin remodeling pathway but also provides an entirely new therapeutic approach for mitochondrial diseases such as Barth syndrome.

{{ptg:RelatedPrimaryAntibodies}}